Bionano Genomics, Inc. (BNGO)

Market Cap	12.18M
Revenue (ttm)	30.78M
Net Income (ttm)	-112.02M
Shares Out	3.01M
EPS (ttm)	-88.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,411
Open	4.100
Previous Close	4.050
Day's Range	4.010 - 4.105
52-Week Range	2.680 - 72.600
Beta	2.09
Analysts	Buy
Price Target	7.00 (+72.41%)
Earnings Date	May 7, 2025

About BNGO

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA lin...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 21, 2018
• Employees: 344
• Stock Exchange: NASDAQ
• Ticker Symbol: BNGO
• Website: https://www.bionano.com

Financial Performance

In 2024, Bionano Genomics's revenue was $30.78 million, a decrease of -14.79% compared to the previous year's $36.12 million. Losses were -$112.02 million, -51.82% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is $7.0, which is an increase of 72.41% from the latest price.

Price Target

$7.0

(72.41% upside)

Analyst Consensus: Buy